A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
- Sponsor:
- TYRA Biosciences
- Sponsor Study ID:
- TYR300-203
- CTO #:
- 104311
- NCT Number:
- NCT07265947
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Other Urinary
- Study Objectives:
- To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants) [Time Frame: within 6 months] Complete response (CR) rate
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Savage, Stephen, at savages@musc.edu
- Study Coordinator, Helpinstill, Sarah, at sah277@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina